China Medical System’s Latest MSCI ESG Rating (867.HK) Remains Unchanged at Global Industry Leader AA

0

HONG KONG, December 30, 2021 / PRNewswire / – Recently, Morgan Stanley Capital International (MSCI), the world’s largest index provider, updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited (“CMS” or the “Company”). CMS’s latest rating remains unchanged at “AA”, surpassing 83% of companies in the pharmaceutical industry, indicating that the company has maintained its leadership position in ESG management among its global peers.

MSCI ESG ratings range from leading (AAA, AA), medium (A, BBB, BB) to lagging (B, CCC) and have covered more than 2,900 companies worldwide. Given its independence, consistency and transparency, ratings have become an important factor affecting the investment decisions of global investors. CMS has maintained the “AA” rating for two consecutive years and has received outstanding ratings in several aspects, such as corporate governance, human capital, product safety and quality, etc., which reflects the recognition of the Company’s governance and sustainable development practices by the capital market.

Pursuing the sustainable development goal of “realizing the concept of environmental protection, achieving the value of social responsibility, committing to become a leading sustainable pharmaceutical company in China“, CMS has always attached great importance to ESG governance and practices. CMS has established an ESG committee at board level in 2020. The committee pays close attention to stakeholder requests and global trends in terms of ESG governance, and continually improve internal operations accordingly, while actively dedicating itself to public welfare and environmental protection. Adhering to the “effort-oriented” concept, CMS considers employees most valuable asset, provides them with comprehensive career paths and actively protects their rights and interests. Additionally, as one of the leading companies in the pharmaceutical industry, CMS adheres to the product quality principles of ” continuous improvement and quality first ”and built the quality control system throughout the product lifecycle, in order to provide accessible, affordable and reliable drugs in order to for the general public.

CMS is committed to further integrating ESG governance into the company’s operations in the future, to meeting its environmental and social responsibilities and to providing more innovative, quality and affordable medicines to meet the clinical needs of patients, in order to create greater values ​​for society.

Contact:
Phone. : +86 755 8241 6868
E-mail:
ir@cms.net.cn

Copyright © acrofan All rights reserved


Source link

Share.

Comments are closed.